<DOC>
	<DOCNO>NCT00438919</DOCNO>
	<brief_summary>This multicenter , prospective , observational registry evaluate safety performance CYPHER SELECT™ Sirolimus-eluting Coronary Stent , future generation commercially approve Cordis Sirolimus-eluting Stents ( SES ) , routine clinical practice . Its objective measure incidence identify predictor acute , sub-acute late stent thrombosis Major Adverse Cardiac Events ( MACE ) . Additional analysis perform patient sub-populations , diabetes , in-stent restenosis ( ISR ) , acute myocardial infarction ( AMI ) multivessel coronary disease .</brief_summary>
	<brief_title>A Multi-center Post-Market Surveillance Registry</brief_title>
	<detailed_description>The data collect consecutive subject treat commercially available product follow standard clinical practice . This registry limit subject receive CYPHER SELECT™ Sirolimus-eluting Coronary Stent index procedure . While inclusion exclusion criterion specify , uniform , complete accurate data collect peri-procedurally , index hospitalization , follow-up . All subject treat accord Instruction For Use ( IFU ) include conduct stenting procedure , application antiplatelet medication medical therapy provide accord local usual practice . Data collection ( Electronic Data Capture ) , data management , statistical analysis , monitor core laboratory evaluation assign independent organization .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>This registry limit subject receive CYPHER SELECT™ Sirolimuseluting Coronary Stent index procedure ; Males females ;</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>